EUVIMEDEUVIMED entdecken
Crossref

CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1

Heping Jin, Zongyang Li, Xinwen Li, Qiongqiong Xu, Beizhong Chen, Song Shan, Desi Pan, Peng Hu, Shengjian Huang iD

Advanced Biology · 2025

DOI: 10.1002/adbi.202400769 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Biology, 2025. Verfasst von Heping Jin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Chengdu Chipscreen Pharmaceutical Corp., Ltd., Chengdu, Sichuan, P. R. China. Hauptthemen laut MEDLINE: Alopecia Areata, Janus Kinase 1, Janus Kinase 3, Protein Serine-Threonine Kinases. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The approval of JAK inhibitors, represented by baricitinib, for the treatment of alopecia areata (AA) has ushered in a new era. However, their excessive immunosuppressive effects have also raised numerous concerns. Therefore, the development of JAK inhibitors with different selectivities may enhance drug safety while maintaining therapeutic efficacy. CS12192, developed by our team, is a selective JAK3 inhibitor that also partially inhibits JAK1 and TBK1. In this study, we evaluate the effectiveness of CS12192 and baricitinib in a C3H/HeJ skin‐transplanted AA mouse model and conduct in‐depth analysis of the similarities and differences in the mechanisms of the two compounds using mass cytometry (CyTOF) and RNA‐seq technology. The results show that CS12192 could reverse hair growth inhibition in AA mice in a dose‐dependent manner, with the high‐dose group exhibiting comparable effectiveness to baricitinib but with better safety. Further research revealed that both compounds significantly reduced the infiltration of immune cells, particularly CD8 + T cells, in the skin of AA animals. CyTOF and RNA‐seq analysis revealed the mechanistic similarities between CS12192 and baricitinib in regulating AA‐related immune cells and signaling pathways. In conclusion, CS12192, as a novel selective JAK inhibitor, holds great potential for the treatment of AA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataJanus Kinase 1Janus Kinase 3Protein Serine-Threonine KinasesAnimalsMiceAzetidinesPyrazolesSulfonamidesPurinesDisease Models, AnimalMice, Inbred C3HSignal TransductionCD8-Positive T-LymphocytesJanus Kinase InhibitorsProtein Kinase Inhibitors

Stichwörter der Autor:innen

Alopecia areataBaricitinibCS12192JAK inhibitors

Substanzen

Janus Kinase 1AzetidinesJanus Kinase 3baricitinibPyrazolesSulfonamidesJak1 protein, mousePurinesJak3 protein, mouseProtein Serine-Threonine Kinases

Autor:innen und Institutionen

  • Chengdu Chipscreen Pharmaceutical Corp., Ltd., Chengdu, Sichuan, P. R. China.
  • Key Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, Shanghai Ocean University, Shanghai, P. R. China.
  • International Research Center for Marine Biosciences, Ministry of Science and Technology, Shanghai Ocean University, Shanghai, P. R. China.
  • Shenzhen Chipscreen Biosciences Co., Ltd., Shenzhen, Guangdong, P. R. China.

ORCID-Profile: Shengjian Huang

Zitieren

APA

Jin, H., Li, Z., Li, X., Xu, Q., Chen, B., Shan, S., Pan, D., Hu, P., & Huang, S. (2025). CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1. Advanced Biology. https://doi.org/10.1002/adbi.202400769

Vancouver

Jin H, Li Z, Li X, Xu Q, Chen B, Shan S, et al. CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1. Advanced Biology. 2025. doi:10.1002/adbi.202400769

BibTeX
@article{Jin2025,
  author = {Jin, Heping and Li, Zongyang and Li, Xinwen and Xu, Qiongqiong and Chen, Beizhong and Shan, Song and Pan, Desi and Hu, Peng and Huang, Shengjian},
  title = {CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1},
  journal = {Advanced Biology},
  year = {2025},
  doi = {10.1002/adbi.202400769}
}
Kostenlos starten →